The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $154.96

Today's change0.00 0.00%
Updated August 26 4:00 PM EDT. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $154.96

Today's change0.00 0.00%
Updated August 26 4:00 PM EDT. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc closed at (U.S.)$154.96.

Shares have lost 6.54% over the last five days, but have gained 3.76% over the last year to date. This security has underperformed the S&P 500 by 28.00% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $154.96
  • High--
  • Low--
  • Bid / Ask(U.S.) $138.11 / (U.S.) $186.00
  • YTD % change+3.76%
  • Volume0
  • Average volume (10-day)338,212
  • Average volume (1-month)366,004
  • Average volume (3-month)477,757
  • 52-week range(U.S.) $89.76 to (U.S.) $217.99
  • Beta-2.24
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$14.04
Updated August 26 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-5,004.71%

Although this company's net profit margin is negative, it is above the industry average and implies that Intercept Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue6000
Total other revenue--------
Total revenue6000
Gross profit--------
Total cost of revenue--------
Total operating expense841288952
Selling / general / administrative42904525
Research & development41374427
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-78-127-89-52
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-77-127-88-51
Income after tax-77-127-88-51
Income tax, total--------
Net income-77-127-88-51
Total adjustments to net income--------
Net income before extra. items-77-127-88-51
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-77-127-88-51
Inc. avail. to common incl. extra. items-77-127-88-51
Diluted net income-77-127-88-51
Dilution adjustment--------
Diluted weighted average shares25242424
Diluted EPS excluding extraordinary itemsvalue per share-3.14-5.17-3.62-2.10
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-3.14-5.17-3.62-2.10